Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

Capsida Biotherapeutics to present preliminary findings on engineered AAV capsids at ASGCT annual meeting

By Brian Buntz | May 11, 2023

CapsidaThe gene therapy platform company Capsida Biotherapeutics (Thousand Oaks, California) is gearing up to unveil initial data on its engineered adeno-associated virus (AAV) capsids at the upcoming American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting, held May 16–20 in Los Angeles.

In developing these capsids, Capsida Chief Scientific Officer Susan Catalano explained that the company employed directed evolution and a high-throughput screening platform to optimize capsid performance across key domains. “We start with a disease and aim to create the best possible therapy, as opposed to trying to mold a disease profile around the limitations of wildtype capsids,” Catalano said.

Preliminary results suggest these engineered AAV capsids can reach up to 68% of neurons across multiple brain regions when delivered intravenously. That finding could translate to new possibilities in gene therapies targeting common neurological diseases that have resisted conventional treatment approaches.

Susan Catalano

Susan Catalano

“A majority of neurological disorders require correction across and throughout many different neural circuits, and it’s only through that extensive circuit coverage that the most meaningful therapeutic benefit will be achieved,” Catalano said, predicting that the company’s capsids could address neurological diseases in extensive adult populations.

Hope for enhanced neuron reach and reduced liver toxicity

Capsida’s initial data showed the reduction of liver transduction by five-fold compared to wild-type AAVs. “High-dose gene therapy utilizing wildtype capsids has been associated with liver toxicity in the clinic, seriously limiting its applications,” Catalano said. In addition to anticipating a considerably lower dosage as a result of optimized efficacy, Capsida anticipates a substantial decrease in liver burden to contribute to the improvement of its capsids’ safety profile.

A fully integrated gene therapy company, Capsida has created a capsid engineering platform that optimizes for capsid tropism and other critical aspects of the capsid contributing to the overall drug substance. “Our platform is focused on engineering an ideal drug substance as opposed to just one aspect of the capsid,” Catalano explained.

Strategic collaborations back Capsida’s mission to combat neurodegenerative and ophthalmology diseases

Capsida collaborators include AbbVie, Lilly and CRISPR Therapeutics. “Each of these partners are seeking approaches to deliver therapeutic cargo to patients with serious neurodegenerative diseases,” Catalano said.

“The therapeutic areas that are the basis for our collaborations with AbbVie, Lilly and CRISPR are focused on CNS diseases,” she added. After forging a collaboration with AbbVie in 2021, the company decided to explore Capsida’s platform more broadly in ophthalmology diseases.


Filed Under: Cell & gene therapy, Neurological Disease, Women in Pharma and Biotech
Tagged With: ASGCT meeting, Capsida, Capsida Biotherapeutics, drug substance engineering, engineered AAV capsids, gene therapy, neurodegenerative diseases, neurological diseases
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at [email protected].

Related Articles Read More >

FUJIFILM Biotechnologies COO Maja Herold Pedersen on AI, autonomy and the path from quality to operations
Cellares raises $257M Series D to automate cell therapy manufacturing
50 cell and gene therapy leaders to watch in 2026
Novartis in the Pharma 50
Novartis bets $200M upfront on Arrowhead’s Parkinson’s RNAi, total value up to $2.2B
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE